Table 1.
Original data extracted from included studies.
| Author, Year | Trial Phase | Type of Tumor |
Sample Size | Mean Age | Male Gender |
Follow-Up (Months) | DCV Regimen | Control Group |
|---|---|---|---|---|---|---|---|---|
| Batich, 2017 [21] | I | ND a | Case: 11 Control (historical): 23 |
55 55 |
8 16 |
60 | pp65 lysosome-associated membrane glycoprotein mRNA-pulsed DCs | 60 |
| Buchroithner, 2013 [23] | II | ND | Case: 19 Control (randomized): 21 |
N/A | N/A | 18 | Not specified | 18 |
| Buchroithner, 2018 [22] | II | ND | Case: 34 Control (randomized): 42 |
54.6 54.0 |
29 22 |
12 | Tumor lysate-charged autologous DCs (Audencel) | 12 |
| Chang, 2011 [24] | I/II | ND | Case: 17 Control (historical): 63 |
45 42 |
N/A | 60 | Phagocytic DCs co-cultured with autologous glioma cells treated by IFN-gamma and heat-shock treatment and then irradiated with 100 Gy | 60 |
| Cho, 2012 [25] | II | ND | Case: 18 Control (randomized): 16 |
52.1 55.8 |
8 8 |
14–56 17–53 |
Whole-tumor lysate pulsed DCs | 14 |
| Jie, 2012 [26] | II | ND | Case: 13 Control (randomized): 12 |
40.2 43.1 |
10 9 |
24 | Autologous glioblastoma-DCs (GBM apoptosis induced by heat-shock) |
22 |
| Leplina, 2007 [27] | Pilot | ND | Case: 39 Control (historical): 80 |
43 46 |
– | 36 | Interferon-induced DCs | 36 |
| Muller, 2015 [28] | II | ND | Case: 117 Control (historical): 165 |
51.0 52.2 |
– | 36 | Not specified | 30 |
| Prins, 2011 [29] |
I | ND | Case: 23 Control (historical): 68 |
53 55 |
16 48 |
60 | Glioma lysate-pulsed DCs booster vaccinations with either imiquimod or poly-ICLC adjuvant | 58 |
| Vik-Mo, 2013 [30] | Pilot | ND | Case: 7 Control (historical): 10 |
57 62 |
– | 24 | Dendritic cell-based vaccine targeting cancer stem cells | 24 |
| Wheeler, 2004 [32] | I/II | ND | Case: 25 Control (randomized): 13 |
54 56 |
16 4 |
48 | Autologous DCs loaded with HLA-eluted peptides from cultured tumor cells or autologous tumor freeze-thaw lysate | 48 |
| Wen, 2019 [31] | II | ND | Case: 75 Control (randomized): 42 |
57.4, 57.5 | 44, 31 | 40 | DCs pulsed with six synthetic peptide epitopes targeting GBM tumor/stem cell-associated antigens MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL13Ra2 | 39 |
| Yamanaka, 2005 [36] | I/II | ND | Case: 18 Control (historical): 27 |
50 56 |
– | 48 | Peripheral blood DCs pulsed with autologous tumor lysate |
48 |
| Yao, 2018 [34] | II | ND | Case: 22 Control (Randomized): 21 |
48, 50 | 13, 11 | 14 | DCs pulsed with glioblastoma stem cell lysates | 12 |
| Yu, 2004 [35] | I | ND | Case: 14 Control (historical): 26 |
46 53 |
10 18 |
60 | Autologous DCs pulsed with autologous tumor lysate | 60 |
a: Not defined.